Item 7.01 Regulation FD Disclosure

On September 29, 2021, Neoleukin Therapeutics, Inc. (the "Company") announced the presentation of data regarding its de novo protein decoy, NL-CVX1, in an oral presentation at IDWeek 2021 titled "Antiviral NL-CVX1 efficiently blocks infection of SARS-CoV-2 viral variants of concern (VOC)" (Conference Track A1, Session [O-27]: Novel Microbial Agents). The IDWeek presentation summarizes research performed by the Company and research collaborators at the Instituto de Medicina Molecular João Lobo Antunes in Lisbon and Hong Kong University. A copy of the presentation materials to be used in the IDWeek presentation is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

The information contained in this Item 7.01, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing by the Company under the Exchange Act or the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such a filing.




Item 8.01 Other Events
On September 29, 2021, the Company issued a press release announcing the IDWeek
presentation described in Item 7.01 above. The full text of the press release
issued by the Company is attached as Exhibit 99.2 to this Current Report on Form
8-K and is incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits

Number                       Description
                               Presentation of Neoleukin Therapeutics, Inc. dated September 29,
99.1                         2021
                               Press Release of Neoleukin Therapeutics, Inc. dated September 29,
99.2                         2021
104                          Cover Page Interactive Data File (formatted as Inline XBRL)

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses